Lack of association between factor V Leiden and thromboembolism in patients with prosthetic heart valves

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 3, 1999, Pages 141-144

  Mammo, Layla ^a   Saour, J N ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Factor V Leiden; Thromboembolism in prosthetic heart valves (PHV)

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HEART VALVE PROSTHESIS; HETEROZYGOTE; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM;

EID: 0032908010     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199904000-00005     Document Type: Article

References (23)

1. Stein PD, Alpert JS, Copeland JG, Dalen JE, Goldman S, Turpie GG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995; 108 (Suppl 4): 3715-3995.
2. Duvoisin GE, Brandenburgh RO, McGoon DC. Factors affecting thromboembolism associated with prosthetic heart valves. Circulation 1976; 35-36 (Suppl 1): 170-176.
3. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-641.
4. Saour JN, Sieck JO, Mammo L, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428- 432.
5. Cannegieter SC, Rosendaal FR, Wintzen AR, Van der Meer FJM, Vandenbroucke JP, Breit E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
6. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 1986; 8 (6 Suppl B): 4113-5613.
7. Vermylen J, Verstraete M, Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol 1986; 8 (6 Suppl B): 2B-9B.
8. Gough SC, Prentice CRM. The investigation of a heart valve patient with suspected hypercoagulability. The J Heart Valve Dis 1993; 2: 7-17.
9. Dahlback B, Carrison MS, Svenson PJ. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
10. Bertina RM, Koeleman PC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
11. Koster T, Rosendaal FR, De Ronde H, Breit E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506.
12. Svensson J, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 300: 517-522.
13. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletick JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
14. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614.
15. Doggen CJM, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-1041.
16. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-2821.
17. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary heart disease. Lancet 1995; 345: 526-527.
18. Halbmayer WM, Houshafer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994; 5: 51-57.
19. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction, Arg 506 to G1n factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.
20. Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction. Lancet 1995; 345:795.
21. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Makelin R, Hamalainen L, et al. Arg 506 G1n factor V mutation (factor V Leiden) in patients with ischemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-560.
22. Mammo L, Al-Dalaan A, Bahabri S, Saour JN. Association of factor V Leiden with Behcet's disease. J Rheumatol 1997; 24: 2196-2198.
23. Dzimiri N, Meyer B. World distribution of factor V Leiden. Lancet 1996; 347: 481-482.